Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
778 Views
eMediNexus 29 December 2017
The US Food and Drug Administration (FDA) has permitted the marketing of the Dermapace System, the first shock wave device intended to be used in the treatment of chronic, full-thickness diabetic foot ulcers with wound areas measuring no larger than 16 cm2 (about the size of a soda can top) which extend through the epidermis, dermis, tendon, or capsule, but without bone exposure. The device is intended for adult patients (22 years and older), presenting with diabetic foot ulcers lasting for more than 30 days, and should be used along with standard diabetic ulcer care.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Benefits of Resistance Training in Boosting Cardiometabolic Health in .....
Impact of Induction Timing on Maternal and Neonatal Outcomes..
COPD: A Potential Risk Factor for Herpes Zoster..
FDA Approves LEQSELVI for Severe Alopecia Areata..
Indolent Rhinovirus Infection in Preschoolers with Recurrent Wheeze: A.....
{{Article_Title}}..
Surge in Suspected Guillain-Barré Syndrome Cases in Pune Triggers Health Alert..
Needle Found in Newborn's Leg Sparks Negligence Allegations against Kannur Hospital..
IMA Warns against 'Mixopathy' While Supporting Alternative Medicine..
Probe Ordered after Govt. Medicines Dumped in J-K's Rajouri..
Anxiety and Relationship Issues Dominate Mental Health Concerns in Delhi: Report..